Icon Plc $ICLR Holdings Decreased by Live Oak Private Wealth LLC

Posted by Geri Gentry on Sep 2nd, 2026

Live Oak Private Wealth LLC trimmed its holdings in shares of Icon Plc (NASDAQ:ICLR – Free Report) by 22.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 16,161 shares of the medical research company’s stock after selling 4,661 shares during the period. Live Oak Private Wealth LLC’s holdings in Icon were worth $2,807,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. WINTON GROUP Ltd acquired a new stake in Icon during the 2nd quarter worth about $254,000. Daiwa Securities Group Inc. increased its holdings in shares of Icon by 19.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock valued at $4,094,000 after purchasing an additional 4,546 shares during the period. Frontier Capital Management Co. LLC increased its holdings in shares of Icon by 97.6% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock valued at $10,379,000 after purchasing an additional 35,253 shares during the period. Peapack Gladstone Financial Corp purchased a new stake in shares of Icon in the second quarter worth approximately $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Icon by 58.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after purchasing an additional 289 shares in the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon Trading Down 2.2%

Shares of NASDAQ:ICLR opened at $161.40 on Wednesday. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $12.36 billion, a PE ratio of 37.89, a P/E/G ratio of 6.83 and a beta of 1.20. Icon Plc has a 1 year low of $66.57 and a 1 year high of $203.91. The firm has a fifty day moving average price of $168.06 and a 200 day moving average price of $134.25.

Icon (NASDAQ:ICLR – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.55 by $0.01. Icon had a return on equity of 8.02% and a net margin of 3.99%.The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. During the same period last year, the company earned $3.26 earnings per share. The business’s revenue was up 2.3% compared to the same quarter last year. Analysts expect that Icon Plc will post 9.58 EPS for the current fiscal year.

Insider Buying and Selling at Icon

In related news, Director Anne Clem Whitaker sold 841 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total value of $138,167.89. Following the completion of the sale, the director directly owned 891 shares in the company, valued at approximately $146,382.39. The trade was a 48.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Nigel Bernard John Clerkin sold 2,267 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total value of $372,445.43. Following the sale, the chief financial officer directly owned 5,881 shares of the company’s stock, valued at $966,189.49. The trade was a 27.82% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 9,531 shares of company stock worth $1,565,764 in the last 90 days. Company insiders own 44.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ICLR shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Icon in a research report on Wednesday, August 26th. Leerink Partners set a $145.00 target price on shares of Icon in a research note on Thursday, May 28th. William Blair upgraded shares of Icon to a “strong-buy” rating in a report on Thursday, July 30th. Mizuho upped their price target on shares of Icon from $180.00 to $190.00 and gave the stock an “outperform” rating in a research note on Friday, June 26th. Finally, BMO Capital Markets increased their price objective on Icon from $160.00 to $187.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $170.40.

View Our Latest Analysis on Icon

About Icon

(Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.